About US
Contact us
-
Merck's Keytruda tops chemo in first-line lung cancer trialMerck & Co. just scored a point in its immuno-oncology rivalry against Bristol-Myers Squibb. The PD-1 checkpoint inhibitor Keytruda hit its goals in a new trial in previously untreated non-small c2016/7/7
-
Latest Sunshine Act fact? Drug and device makers shelled out $6.5B to docs, hospitals last yearDrug and device makers handed over almost $6.5 billion to doctors and medical institutions in 2015, according to the latest release from the U.S. government’s Open Payments database. Add in various ow2016/7/6
-
Spain's Almirall eyes embattled Valeant's dermatology assetsTroubled Valeant may have a buyer to help it pull off some of the asset sales it’s been touting as it looks to cut down its debt pile. Spain’s Almirall, for one, is eyeing some of the company’s meds,2016/7/6
-
Jury smacks J&J with $70M in damages in latest Risperdal breast caseJohnson & Johnson ($JNJ) is fighting more than 1,500 legal claims that its antipsychotic Risperdal triggered breast development in boys, and the company has landed on the wrong side of a jury verd2016/7/5
-
Exclusive deal with Gilead on hep C to cut Massachusetts Medicaid costsFederal Medicaid officials lectured Gilead Sciences and other hep C drugmakers last year on the need to find ways to cut prices on their pricey meds for state Medicaid programs. Now, Massachusetts say2016/7/5
-
Arena chops 100-plus jobs as it shifts its priorities from struggling BelviqObesity med Belviq hasn’t been coming through for Arena ($ARNA)--and the drugmaker has seen enough. It’s changing up its priorities, but the move will cost 100 workers their jobs. The company is slas2016/7/4
-
Pfizer, Amgen most likely to bid for Medivation: analystsWith several Big Pharma players rumored to be interested in Medivation, plenty of industry watchers see another bidder potentially jumping into the mix to thwart Sanofi’s hostile quest. But which amon2016/7/4
-
GSK’s MenABCWY vaccine set to reshape meningococcal space, report saysAnticipated to grow to $1.8 billion by 2025, the global meningococcal vaccines market could see some big changes over the next decade. Pending successful late stage trials, GlaxoSmithKline’s forthcomi2016/7/1
-
Allergan's brand recognition, rebates keep aesthetics unit primed for growth: SpecialistsGood news for Allergan: The aesthetics market--which has lately been on the rise--is showing no signs of slowing down. At least, that’s the word from aesthetic specialists grilled by Leerink Partners2016/7/1
-
Pfizer to invest in new global biotechnology centre in ChinaAmerican-based pharmaceutical company Pfizer will invest nearly $350m to build a latest Global Biotechnology Centre in the Hangzhou Economic Development Area (HEDA), China. The modern HEDA facility i2016/6/30